尽管股票业绩波动和季度亏损,Oncologiologics仍获得“Neutral”评级。 Oncobiologics receives "Neutral" rating despite volatile stock performance and quarterly loss.

一家生物制药公司Oncobiologics获得分析师的“Neutral”评级, 协商一致的目标价格为9. Oncobiologics, a biopharmaceutical company, has received a "Neutral" rating from analysts, with a consensus target price of $9.60. 该公司的股票营业量为0.85美元,波动幅度很大,一年一度最高,为8.32美元,最低,为0.79美元。 The company's stock opened at $0.85, showing significant volatility with a one-year high of $8.32 and a low of $0.79. Oncobiologics 报告季度亏损每股 0.44 美元，略低于分析师预期。 Oncobiologics reported a quarterly loss of $0.44 per share, slightly missing analyst estimates. 该公司的市场上限是3 781万美元。 The company has a market cap of $37.81 million.